Royalty Pharma (NASDAQ:RPRX) Announces Quarterly Earnings Results, Misses Expectations By $0.86 EPS

Royalty Pharma (NASDAQ:RPRX) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.32 EPS for the quarter, missing the consensus estimate of $1.18 by ($0.86), FiscalAI reports. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. The company had revenue of $690.10 million for the quarter, compared to analyst estimates of $884.84 million.

Here are the key takeaways from Royalty Pharma’s conference call:

• Royalty receipts grew 9% in the quarter and 12% year to date, led by products including TREMFYA, Voranigo, Evrysdi and IMDELLTRA; growth absorbed an approximately 5% combined headwind from Promacta and IMBRUVICA.
• Royalty Pharma raised its 2026 guidance for the third consecutive quarter, now expecting portfolio receipts of $3.5 billion–$3.55 billion and royalty-receipt growth of 10%–11%.
• Management highlighted commercial and pipeline opportunities, including strong IMDELLTRA first-line data, FDA approvals for RASONQUE and WELTRUZA, and five successful pivotal Phase III trials so far in 2026. The company also cited a dozen potential blockbuster launches and more than $1.7 billion in potential future peak royalties from its development-stage pipeline.
• Novartis’ pelacarsen failed its Phase III outcomes trial, resulting in a $150 million non-cash impairment. Royalty Pharma said the investment was structured to limit the downside, with SPINRAZA royalties expected to provide $550 million against $500 million funded, a 1.1x return.

Royalty Pharma Stock Performance

NASDAQ RPRX traded up $0.59 during trading on Wednesday, reaching $66.99. The company’s stock had a trading volume of 2,016,930 shares, compared to its average volume of 3,408,460. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.80 and a current ratio of 2.80. The firm has a market cap of $38.52 billion, a price-to-earnings ratio of 46.21, a P/E/G ratio of 1.82 and a beta of 0.37. Royalty Pharma has a twelve month low of $36.03 and a twelve month high of $67.71. The business’s fifty day moving average price is $60.48 and its 200-day moving average price is $53.39.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a dividend of $0.2350 per share. This represents a $0.94 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, November 13th. Royalty Pharma’s dividend payout ratio (DPR) is presently 64.83%.

Insider Transactions at Royalty Pharma

In other news, EVP Marshall Urist sold 4,126 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the transaction, the executive vice president directly owned 270,401 shares in the company, valued at approximately $15,826,570.53. This represents a 27.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 208,252 shares of company stock valued at $12,324,407 over the last ninety days. Corporate insiders own 18.84% of the company’s stock.

Wall Street Analysts Forecast Growth

RPRX has been the subject of several research analyst reports. Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 26th. JPMorgan Chase & Co. upped their target price on Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Bank of America restated a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Finally, TD Cowen lifted their price target on Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Eight analysts have rated the stock with a Buy rating. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $61.57.

About Royalty Pharma

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.